期刊文献+

SP/NK-1R及其与子宫内膜癌的关系 被引量:1

Study on SP/NK-1R and Its Relationship with Endometrial Cancer
暂未订购
导出
摘要 随着分子生物学和免疫学的发展,源自中枢组织的P物质(SP)因其广泛分布于人体各个组织而成为研究的热点。SP主要通过与其特异性受体神经激肽1受体(NK-1)结合而具有多种生物学活性,比如诱导炎症环境,促进肿瘤细胞的神经向性,诱导肿瘤细胞的增殖、迁移及促进胰岛素抵抗,上述机制与子宫内膜癌的发病及预后关系密切,可作为临床诊治子宫内膜癌的一个新靶点。因此,本文就该因子的生物学功能、在肿瘤方面的作用及其与子宫内膜癌的关系进行综述。 With the development of molecular biology and immunology,substance P(SP)derived from central tissues has become a research focus due to its widespread distribution in various human tissues.SP mainly has a variety of biological activities by binding to its specific receptor neurokinin 1 receptor(NK-1),such as inducing an inflammatory environment,promoting the neurotropy of tumor cells,inducing the proliferation,migration and promotion of tumor cells Insulin resistance,the above mechanism is closely related to the incidence and prognosis of endometrial cancer,and may become a new target for clinical diagnosis and treatment of endometrial cancer.This article reviews the biological function of the factor,its role in tumors,and its relationship with endometrial cancer.
作者 谭晓瑜 黄金智 赖锦胜 宋硕 陈国通 郑楚丽 陈智丹 TAN Xiao-yu;HUANG Jin-zhi;LAI Jin-sheng;SONG Shuo;CHEN Guo-tong;ZHENG Chu-li;CHEN Zhi-dan(Guangdong Medical University,Zhanjiang 524001,Guangdong,China;Department of Obstetrics and Gynecology,the Affiliated Hospital of Guangdong Medical University,Zhanjiang 524002,Guangdong,China)
出处 《医学信息》 2020年第7期29-32,共4页 Journal of Medical Information
基金 广东省自然科学基金项目(编号:2017A030313559)。
关键词 SP/NK-1R 肿瘤功能 子宫内膜癌 SP/NK-1R Tumor function Endometrial cancer
  • 相关文献

参考文献8

二级参考文献76

  • 1廖利民.尿动力学技术规范——介绍国际尿控协会标准化报告[J].中国康复理论与实践,2005,11(11):875-878. 被引量:32
  • 2郎景和.子宫内膜异位症研究的任务与展望(之一)[J].中华妇产科杂志,2006,41(5):289-290. 被引量:125
  • 3马岳.HBV、HCV感染影响红细胞、血小板指数的差异[J].检验医学,2006,21(6):673-675. 被引量:5
  • 4Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nature reviews cancer, 2004,4.- 505-518.
  • 5Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature reviews cancer, 2008,8 : 915-928.
  • 6Chitnis MM, Yuen JS, Protheroe AS, et al. The type 1 insu lin like growth factor receptor pathway. Clin Cancer Res, 2008,14:6364 6370.
  • 7Saehdev D , Yee D. Disrupting insulin-like growth factor signa ling as a potential cancer therapy. Mol Cancer Ther, 2007,6: 1-12.
  • 8Giovannucci E, Hahei LA, Harlan DM, et al. Diabetes and cancer: a consensus report. Diabetes Care, 2010,33:1-12.
  • 9Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy fortype2 diabetes. Diabetes Care, 2009,32 Suppl 2:S253-S259.
  • 10Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of re-ceptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes, 2000, 49: 999-1005.

共引文献51

同被引文献1

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部